Supplementary Figure S5 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy

Key Points

• Blinatumomab shows steady state concentrations in both adult and pediatric patients receiving chemotherapy.
• Concentration levels vary by patient weight and age, highlighting individual differences in drug metabolism.
• Data include subgroups of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
• Observational analysis across patient demographics demonstrates the importance of tailored therapy in leukemia treatment.